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Abstract
Pulmonary hypertension represents a group of conditions characterized by higher than normal pulmonary artery
pressures. Despite improved treatments, outcomes in many instances remain poor. In recent years, there has been
growing interest in the use of Cardiovascular Magnetic Resonance (CMR) in patients with pulmonary hypertension.
This technique offers certain advantages over other imaging modalities since it is well suited to the assessment of
the right ventricle and the proximal pulmonary arteries. Reflecting the relatively sparse evidence supporting its use,
CMR is not routinely recommended for patients with pulmonary hypertension. However, it is particularly useful in
patient with pulmonary arterial hypertension associated with congenital heart disease. Furthermore, it has proven
informative in a number of ways; illustrating how right ventricular remodeling is favorably reversed by drug
therapies and providing explicit confirmation of the importance of the right ventricle to clinical outcome. This
review will discuss these aspects and practical considerations before speculating on future applications.
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Background
Pulmonary hypertension (PH) is the term given when
mean pulmonary artery pressure (mPAP) is greater or
equal to 25 mmHg [1]. It also describes a collection of
clinical conditions in which pulmonary artery pressures
are elevated.
At the most recent World Health Organisation confer-
ence (Dana Point, California) in 2008, PH was classified
into five distinct disease groups (Table 1). Group 1 fea-
tures patients with pulmonary arterial hypertension
(PAH) and represents the most widely investigated sub-
set of PH. It is thought to occur in 15-50 persons per
million. Although newer treatments have led to
improved survival, the disease continues to be associated
with a poor prognosis [2].
For each patient, a methodical approach is necessary
to describe the cause(s) of PH. Alongside right heart
catheterisation, multimodality imaging plays a key part
in this [3]. Echocardiography is the best screening test
for PH whilst radioisotope ventilation-perfusion scan-
ning remains the principal modality for the diagnosis of
chronic thromboembolic pulmonary hypertension
(CTEPH, Group 4). In patients with CTEPH being con-
sidered for pulmonary endarterectomy, computed tomo-
graphy (CT) helps determine operative suitability. High
resolution CT is used to characterize lung disease.
It is twenty five years since the use of cardiovascular
magnetic resonance (CMR) was first reported in PH [4].
Due to its spatial resolution and freedom from acoustic
windows, it has emerged as the gold standard for assess-
ment of right ventricular (RV) structure and function
[5,6]. This is particularly important in PH where the RV
has long been thought to be important to survival [7].
Despite this, current guidelines rank other modalities
more highly [1]. Though not surprising given CMR’s
limited availability and evidence base, experience with
this technique is accumulating rapidly. It therefore
seems unlikely that its position in future guidelines will
remain unchanged.
The CMR examination is focused on the right heart
and pulmonary arteries which undergo characteristic
changes in response to elevated pulmonary pressures
(Table 2). It is thought that RV hypertrophy initially
predominates to compensate for pressure overload [1]
before RV dysfunction and dilatation occur. The devel-
opment of tricuspid regurgitation exacerbates volume
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any medium, provided the original work is properly cited.overload. RV failure causes right atrial (RA) pressure [7]
and size [8] to increase; both of which are related to
outcome. Falling RV stroke volume and abnormal inter-
ventricular septal motion attenuate left ventricular (LV)
filling and stroke volume. The proximal PAs become
dilated. Histologically evident structural changes include
media thickening and accumulation of mucopolysac-
charide ground substance [9].
Practical Considerations for CMR in PH
Indications, Protocol and Interpretation of Findings
Patients may be referred with an established diagnosis of
PH, with a diagnosis that requires clarification or with
PH of unknown aetiology. Conversely, features of PH
may be unexpectedly encountered in patients referred
with left heart disease (where they should be reported
due to its prognostic importance) or in patients with
dilated RVs previously thought to have arrhythmogenic
right ventricular dysplasia.
A minimum data set should allow RV size and func-
tion to be assessed by quantifying biventricular volumes,
ejection fraction (EF) and mass. RV and LV stroke
volume can be derived by flow mapping of the main
pulmonary artery and aorta respectively. When
reporting cardiac output and index, flow mapping of the
aorta should be used [10] since it is smaller, has more
coherent flow patterns and less translational movement
than the main pulmonary artery. In instances where
thromboembolic disease has not previously been
excluded, an MR angiogram (MRA) of the pulmonary
arteries should be undertaken. The examination is com-
pleted with imaging of late gadolinium enhancement
(LGE). A suggested protocol is shown in Table 3.
I ti sn o tp o s s i b l et oc o n s i s t e n t l yi d e n t i f yac a u s eb y
CMR alone. However, in selected cases a specific under-
lying disease may be suggested by the presence of one
or more features (Table 1). It is important to integrate
these findings with the examination, being prepared to
deviate from this protocol to allow a more detailed
assessment at the same sitting.
In patients with features suggestive of shunt, dedicated
anatomical imaging, cines, flow mapping and angiogra-
phy should be undertaken. CMR is particularly helpful in
the diagnosis of a sinus venosus defect and partial anom-
alous venous drainage [11] (Figure 1). If evidence of myo-
cardial infarction or significant valvular heart disease
e x i s t s ,l e f th e a r tc a u s e s( G r o u p2 )b e c o m em o r el i k e l y .
Diastolic dysfunction should be considered when LV
Table 1 Classification of PH and Pointers to Each Subset
Dana Point
Clinical Classification
Flags Suggested Sequences
Group Name
1. PAH Shunts, aberrant pulmonary veins Dedicated views, flow
mapping and MRA
2. Left heart disease LV impairment, hypertrophy or wall motion abnormalities, dilated left atrium,
valvular disease
Pulmonary vein stenosis
LGE and valve lesion
quantification
Cine SSFP, flow and MRA
3. Lung diseases and/or
hypoxia
Emphysematous or fibrosed lung fields. However compared to high-resolution
computed tomography, CMR images lungs poorly
4. CTEPH Filling defects in the pulmonary arteries MRA
5. Unclear and/or
multifactorial mechanisms
Lymphadenopathy
Absent spleen
LGE
PAH; Pulmonary arterial hypertension, CTEPH; chronic thromboembolic pulmonary hypertension, MRA; magnetic resonance angiography, LGE; late gadolinium
enhancement SSFP: steady state free procession.
Table 2 Right Heart Changes in Pulmonary Hypertension
RV hypertrophy involving the papillary muscles, trabeculations and interventricular septum [72]. Asymmetric septal hypertrophy may be present
[73-75]
Progressive RV dilatation until it becomes the dominant, apex-forming ventricle
Abnormal interventricular septal motion
Tricuspid regurgitation as a consequence of RV dilatation and stretching of the valve annulus
Interatrial septum becomes convex leftwards reflecting elevated RA pressures
Dilated RA
Plethoric vena cavae
Pericardial effusion
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Sequence Objective Slice
Prescription Parameters
Localisers Identify the position of the heart Sagittal, coronal and axial
planes
Cines Define axes of both ventricles and
the great arteries
HLA, VLA, SAX stack, LVOT,
LVOT cross cut, RV VLA, MPA,
MPA cross cut
Retrospectively gated, steady state free procession, slice
thickness 7 mm, interslice gap 3 mm, FOV read 340 mm,
FOV phase 75 mm
Flow
Measurements
To determine stroke volume through
main pulmonary artery and aorta
MPA/Ao Retrospectively gated,2D segmented Spoiled Gradient Echo
sequence. Slice thickness 10 mm, FOV read 350 mm, FOV
phase 100 mm
Magnetic
Resonance
Angiography
To assess the pulmonary arterial tree Ensure coverage of the lung
vasculature
Non-ECG gated 3D Spoiled Gradient Echo sequence, slice
thickness 1.30 mm, FOV read 400 mm, FOV phase 100 mm
Late
Gadolinium
Enhancement
To exclude areas of infarction and
determine the degree of insertion
region enhancement
Short axis stack and long axis
acquisitions
2D segmented Spoiled Gradient Echo sequence with non-
selective inversion pulse sequence. Slice thickness 8 mm,
FOV read 340 mm, FOV phase 75 mm. LGE TI 260 mm
initially then alter accordingly
HLA; horizontal long axis, VLA; vertical long axis, SAX; short axis, LVOT; left ventricular outflow tract, RV; right ventricular, MPA; main pulmonary artery, Ao; aorta,
FOV; field of view, LGE; Late Gadolinium Enhancement, TI, inversion time.
Figure 1 Cardiovascular Magnetic Resonance in Group 1 PAH due to Congenital Heart Disease. Top left, In plane flow mapping
demonstrating flow between left and right atrium (arrow) through an atrial septal defect; Top right, a steady state free procession cine showing
flow (asterisk) from descending aorta to pulmonary artery via a persistent ductus arteriosus; Bottom left, Magnetic Resonance Angiography of an
aberrant pulmonary vein (arrow) draining into the right atrium (RA); Bottom right, flow mapping in this patient in the main pulmonary artery
and aorta allowed a Qp:Qs of 2.7 to be derived.
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absence of other causes, especially in patients with dia-
betes and systemic hypertension. Pulmonary vein steno-
sis, either idiopathic or occurring after atrial fibrillation
ablation therapy [12], can cause PH. The severity of the
stenosis can be quantified by flow mapping and visua-
lized with MRA (Figure 2).
Chronic thromboembolic disease can be identified
using MRA (Figure 2). However, thrombosis arising in-
situ can also be found in non-Group 4 patients, particu-
larly in those with Eisenmenger syndrome [13]. More
rarely, sarcomas can mimic pulmonary emboli. T1
weighted imaging following injection of gadolinium [14]
may be helpful in differentiating the two. A combination
of mediastinal lymphadenopathy and a non-coronary pat-
tern of LGE is suggestive of cardiac sarcoid. An absent
spleen is an important finding as it is associated with a
higher risk of PH [15].
Acquisition of Volumetric Data
In routine practice, volumetric data is acquired by align-
ing the short-axis stack to the LV [16]. In PH, this cre-
ates several difficulties. Firstly the RV can dilate beyond
the atrioventricular groove, when it appears as a
‘shoulder’ surrounding the right atrium in the basal
short axis. In these cases, end-diastolic RV volume will
be underestimated unless the short-axis starts within the
atria (Figure 3). Secondly, in severe RV systolic impair-
ment, atrioventricular excursion may not exceed slice
thickness. In these instances, the basal slice may contain
RV instead of RA at end-systole. To help discriminate
RV from RA, atrioventricular excursion should be
estimated by cross-referencing short-axis slices against
each long axis acquisition [17,18]. Tracking an object’s
motion between slices and frames may also be useful.
It has been suggested that by orientating ventricular
acquisition axially [19] or perpendicular to the long axis
of the RV [20] these problems will be circumvented.
Whilst these approaches improve interobserver reprodu-
cibility [19] and reduce differences between right and
left ventricular volumes [20], they have not been
adopted more widely. In addition, values obtained in
this manner cannot be easily compared with normal
values established using ‘biventricular’ analysis [21,22].
These factors argue in favor of the continued use of
conventional analysis in patients with PH.
Analysis of Right Ventricular Indices
There is no consensus as to how RV analysis should be
performed. This has become an increasingly relevant
issue as enhanced spatial resolution has allowed indivi-
dual RV papillary muscles and trabeculae to be visua-
lized. Acknowledging that these structures and the
interventricular septum hypertrophy in PH, in our cen-
tre total RV mass includes the papillary muscles and tra-
beculae, as well as the ‘RV’ septum [23] when the
interventricular septum is hypertrophied.
Manual analysis offers better control over delineation
than semi-automated analysis, reflected in improved
interobserver reproducibility [23]. However it is time
consuming and requires end-systole to be predefined.
This can be difficult in PH due to abnormal interventri-
cular septal motion. One labor-intensive approach is to
determine biventricular volumes in the frame exhibiting
Figure 2 Abnormalities of Pulmonary Vasculature in Pulmonary Hypertension.; (A) White blood anatomy showing right upper pulmonary
vein stenosis at the site of a prior ablation for atrial fibrillation (arrow). (B) Congestion and infarction in the right upper lobe on Half-Fourier
Acquisition Single-Shot Turbo Spin-Echo images in the same patient (asterisk). (C) Magnetic Resonance Angiography from a separate patient
with PH due to fibrosing mediastinitis; a varix is seen bypassing a stenosed left upper pulmonary vein (not shown) alongside stenoses of both
right sided pulmonary veins (arrows). (D) Magnetic Resonance Angiography in patient with Chronic Thromboembolic Pulmonary Hypertension.
The most striking feature is loss of the left descending pulmonary artery (arrow head).
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ing it, before choosing the smallest volume as end-sys-
tole for each ventricle. Alternatively, end-systole can be
defined using valve opening and closure.
To simplify RV assessment, surrogate measurements
have been developed. One candidate is analysis of trans-
verse motion, which proved to be more strongly corre-
lated with ejection fraction than tricuspid annular plane
systolic excursion [24].
Late Gadolinium Enhancement
The finding of LGE limited to the insertion regions
(Figure 4) has been repeatedly demonstrated [25-27] in
PH since first described in 2005 by McCann and collea-
gues [28]. This has led to speculation that it may reflect
pathological fibrosis [25] and hence be a source of ven-
tricular arrhythmias [26]. Proving its histological basis
has been difficult. In one of the very few pathology stu-
dies of the heart performed in PH, this area was not
inspected [29]. In addition, its position is inaccessible to
in-vivo biopsy. Pathological correlation in a patient who
had died 6 weeks after CMR [30] showed myocardial
disarray and plexiform fibrosis at the insertion regions
where LGE occurred. These histological features are
normally found in the insertion regions since they repre-
sent crossing points for left and right ventricular fibres
with collagen in between [31]. Hence LGE may reflect
pooling of gadolinium within an area of normal myocar-
dium whose architecture has been accentuated by
hypertrophy and mechanical stress.
Non-Invasive Assessment of Haemodynamics
The ability to non-invasively estimate pressures within
the right heart is a key objective since it would permit
diagnosis and serial assessment without cardiac catheteri-
zation. Unfortunately, unlike echocardiography, it is not
possible to generate an estimate of RV systolic pressure
by measuring the velocity of the tricuspid regurgitant jet.
This is because the tricuspid regurgitant jet is dispersed,
Figure 3 Basal Slice Analysis. In the normal right ventricle (A) the angle between the left ventricular long axis (black dashed line) and basal
slice (dashed white box) is approximately 90°. In PH patients (B), assuming the basal slice is prescribed as per recommendations [16] the angle
becomes more obtuse as the right ventricle dilates. The basal slice will now include right atrium (seen centrally) with a shoulder of right
ventricle seen laterally (C, arrow heads). The impact this interpretation has on delineation is shown in D. Also in B note how the most basal part
of the right ventricle ‘hoods’ beyond the TV plane (arrows) and is effectively ignored by the acquisition.
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through-plane or in plane acquisitions [32] (Figure 5).
Pulmonary pressures have been estimated by measur-
ing the effects of PH on the heart. Initial results were
encouraging for RV mass [33] but have been mixed sub-
sequently [34]. Based on recent results, the degree of sep-
tal displacement may be a more promising measure [35].
CMR derived flow in the main pulmonary artery has
also been used to gauge hemodynamics. For example,
pulmonary pressures were shown to be inversely corre-
lated with average blood velocity in the main PA [36]. In
addition, total pulmonary resistance has been estimated
by determining the percentage of regurgitant flow and
c r o s s - s e c t i o n a la r e ao ft h em a i np u l m o n a r ya r t e r y[ 3 7 ] ,
or calculating the ratio of the maximal change in flow
rate during ejection to the acceleration volume [38].
Finally, the use of four dimensional flow [39] has built on
early work in two dimensional flow [40], to show that in
patients with PH, a vortex can be detected in the primary
flow direction whose duration correlates well with mPAP.
End-organ effects on the PAs themselves can also be
assessed since their distensibility is reduced in PH [41].
It has been shown that a fractional change in the cross-
sectional area of the main PA of less than 40% has a
high sensitivity for detecting elevated mPAP [42]. Addi-
tionally, compliance has been calculated by combining
velocity-encoded data and cross-sectional area change of
t h em a i nP Aa n dd e r i v i n gp u l s ep r e s s u r et h r o u g ha n
iterative process [43]. From this, pulse wave velocity
(PWV, a measure of vessel stiffness) was derived which
had a reliability percentage of 87% for framing the
actual mPAP.
PWV can be calculated directly using the transit time
technique by determining flow wave arrival time at two
points in the proximal PAs using a high-temporal reso-
lution flow mapping sequence (Figure 6), and dividing
the difference by the distance between them [44]. This
calculation does not depend on a prior knowledge of PA
pressure and raises the possibility of entirely non-inva-
sive assessment of PA stiffness.
The sheer number of indices emphasizes the lack of a
single, robust non-invasive measure. Indeed in one inde-
pendent validation [34], none of the tested parameters
accurately predicted mPAP. For CMR to replace cardiac
Figure 4 The characteristic late gadolinium enhancement pattern of PH. (A-C) insertion region enhancement (arrows) is triangular in shape
with the base at the epicardial surface where both ventricles meet and its apex directed into the interventricular septum. Corresponding short
axis cine slices (D-F). The septomarginal trabeculation is arrowed (E) - enhancement is often seen within this structure.
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atrial pressure also needs to be estimated. Early work
has shown this might be possible through the measure-
ment of transmitral flow and myocardial tissue velocity
(i.e. akin to tissue Doppler imaging in echocardiography)
[45].
Determining Treatment Effect and Prognosis
C M Ri sw e l ls u i t e dt ol o n g i t u d i n a lf o l l o wu pa si ti s
non-invasive and non-ionizing. Several studies have
reported the positive effects medical [46-49] and surgical
[50-54] therapies have on RV structure and function.
CMR has also been used to determine which patients
with idiopathic PAH might benefit from long-term cal-
cium channel blockade by assessing main PA distensibil-
ity [55].
This has driven interest in the use of CMR to measure
efficacy of new therapies. To date, two proof of concept
trials [48,56] have used CMR-derived RV mass as an
end-point. This particular surrogate remains unvalidated
and may not be the best end-point since it is not known
whether a reduction in RV mass is beneficial or harmful
to patients.
Using CMR as a trial end-point remains an attractive
option since it avoids the limitations associated with the
most widely use surrogate in PAH trials; the six minute
walk test distance [57]. In addition, fewer patients are
required due to its high interstudy repeatability [23].
The RV has been implicated in clinical outcomes from
the earliest right heart catheterization studies which
showed parameters which could be related to this ven-
tricle (cardiac output, RA pressure and mixed-venous
oxygen saturations) were relevant to prognosis [7,58].
However it has only been with maturation of single-cen-
t r ee x p e r i e n c e( t h eV UU n i v e r s i t yM e d i c a lC e n t e ri n
Amsterdam, The Netherlands) that this assumption has
been proven with CMR.
The first outcome study to be reported with CMR [59]
demonstrated the importance of indexed biventricular
dimensions; a relationship that had not been hitherto
revealed by echocardiographic studies. Indexed RV end-
diastolic volume was prognostic both at baseline (Figure 7)
Figure 5 Chasing Tricuspid Regurgitation. Accurate jet velocity analysis depends on two factors; positioning of the imaging slice through the
jet core and jet core characteristics. The latter is where measurement of tricuspid regurgitation with CMR falls down; compare the discrete
stenotic lesion as might be seen in aortic stenosis (left) to the dispersed jets of tricuspid regurgitation (right) and how they relate to the imaging
plane (represented by boxed line with direction of velocity measurement arrowed, modified with permission [32]). In functional tricuspid
regurgitation, the jets arise at a number of points of failed coaptation and so are numerous and narrow - meaning their core is rarely large
enough to be measured.
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diastolic volume. These data have recently been extended
to include RV ejection fraction [60]. CMR parameters of
PA stiffness are also relevant to prognosis [61] (Figure 7).
This emphasizes the point that as the PA become stiffer
their ability to buffer pulsatile blood is lost. The RV must
compensate for this by generating additional energy to
propel blood downstream.
Providing Pathophysiological Insights
CMR has offered a number of wide-ranging insights into
the pathogenesis of PH through diverse applications
(Table 4). By measuring PA distensibility, it has been
shown that in patients with normal pulmonary pressures
at rest but detectable PH with exercise, the PAs are stiffer
than in normal subjects [42]. The authors speculated that
this increased stiffness may itself play a role in accelerat-
ing pulmonary vascular remodeling. CMR has demon-
strated that left ventricular mass is lower than normal in
patients with CTEPH before pulmonary endarterectomy
but normalizes afterwards [62]. This is thought to be due
to myocardial apoptosis of the chronically underfilled LV.
Using tagging, it has been observed that the RV in PH
contracts more slowly than the LV creating interventricu-
lar dyssnchrony and subsequent interventricular septal
bowing [63].
During CMR perfusion with adenosine stress in
patients with PH, biventricular vasoreactivity has been
Figure 6 Measuring Transit-Time PWV in the Pulmonary Arteries. Data is acquired in main pulmonary artery, left and right pulmonary artery
(A) and the path length between them measured accurately. Using CMR phase-contrast velocity maps (B), the flow pulse is tracked (C) and
differences (T) in arrival time (D, in this healthy case defined as halfway between the foot and maximum values) are determined. PWV is then
calculated as T/Pathlength. MPA; main pulmonary artery, RPA; right pulmonary artery, LPA; left pulmonary artery, BPA; branch pulmonary artery,
PWV; Pulse wave velocity.
Figure 7 The RV-PA unit and Survival in PAH. Work from the VU University Medical Center (Amsterdam) group demonstrating the
importance of right ventricular dilatation [59] (A), ejection fraction[60] (B), and pulmonary artery stiffness [61](C) to prognosis. RVEDVI; indexed
right ventricular end-diastolic volume, RVEF; right ventricular ejection fraction, RAC; relative area change.
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in both ventricles could be predicted from mPAP [64].
Despite its potential, nuclear magnetic resonance
(NMR) spectroscopy remains relatively unexplored in
PH. An isolated case report using 31P-NMR spectro-
scopy offers a unique insight into the failing RV by
showing how RV energetics are disturbed in PAH but
improve with bosentan treatment [65].
Interventional CMR allows RV pressure-volume loops
to be created from which three key measures are
extracted: 1) Systolic function (Emax; end-systolic pres-
sure divided by end-systolic volume, 2) Afterload (Ea;
end-systolic pressure divided by stroke volume) and 3)
Ventricular-arterial coupling (Emax/Ea). In patients with
PAH, Kuehne and colleagues [66] found that while sys-
tolic function was increased, the increase in arterial ela-
stance was relatively greater leading to ventricular-
arterial decoupling. These findings have been echoed
more recently in a larger cohort of patients with PH
(albeit using different definitions of Emax and Ea) [67].
Exercise CMR, performed on a recumbent bicycle
within the scanner, has been used to demonstrate that
exercise-induced increases in cardiac output in patients
with idiopathic PAH are due to heart rate changes alone,
s i n c es t r o k ev o l u m ef a i l st oa u g m e n t[ 6 8 ] .C M Rh a sa l s o
detailed inaccuracies with the Fick method for determin-
ing cardiac output in conditions of high pulmonary blood
flow or increased oxygen concentration [69].
Future Directions
C M Ri su n l i k e l yt ob em o r ew i d e l yi n t e g r a t e di n t oa
general imaging pathway in PH until its incremental
value is proven in routine clinical practice. To determine
whether this is the case, clinical trials of CMR imaging
should be undertaken comparing standard care in PH
with that informed by CMR results. It is also important
that analysis become standardized and facilitated by
improved software.
It has also been suggested that CMR be used to
‘screen’ potential therapies before they are selected for
definitive, long-term studies [70]. Before doing so, CMR
parameters need to be validated [71]. One aspect of this
involves determining which of the available measures
best reflects prognosis. This should include an explora-
tion of load-independent end-points, such as ventricular
tagging.
Like most research in PH, CMR-based work has been
mainly applied to Group 1 (PAH). It remains unclear
whether the RV in each group behaves differently in the
face of similar pulmonary pressures. Through contem-
poraneous assessment of the RV-PA functional unit,
CMR might be able to contribute to an answer, and if
this assertion is correct, explain why.
Work should continue to define the relevance of flow
wave morphology and pulmonary artery stiffness with
focus extended to non-invasively determining left atrial
pressure. The opportunity to validate this work is
Table 4 New Insights Provided by CMR
INSIGHT CMR METHOD REF#
Early Changes
PA stiffens before pulmonary artery pressure increase at rest Distensibility of pulmonary arteries [42]
Ventricular Remodeling and Dysfunction
LV mass is lower in patients with chronic thromboembolic disease but normalizes
post-pulmonary endarterectomy
LV mass [62]
Interventricular dyssnchrony and septal bowing in PAH is due to slower contraction for
the RV than LV
Tagging [63]
Cardiac Ischemia
Both ventricles display attenuated vasoreactivity proportional to mPAP Adenosine Stress Perfusion [64]
RV Metabolism
Bosentan improves RV energetics 31P-NMR spectroscopy [65]
Ventricular-arterial Decoupling in PH
Disconnect occurs since increases in arterial load are far greater than those in
contractility
Volumes combined with invasively derived
pressure loops/pressures
[66,67]
Changes with Exercise
Stroke volume in PAH fails to augment - increases in cardiac output are mediated by
heart rate alone
Bicycle exercise [68]
Inaccuracy of Catheter-Laboratory Measurements
Pulmonary vascular resistance derived from the Fick method is inaccurate in conditions
of vasodilatation
Flow combined with invasively derived pressure [69]
CMR; cardiovascular resonance imaging, PH; pulmonary hypertension, LV; left ventricle, RV; right ventricle, mPAP; mean pulmonary artery pressure, PAH;
pulmonary arterial hypertension
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animal CMR is being explored although it should be
acknowledged that animal models of PAH are unreliable
in predicting human responses.
Conclusions
CMR permits an accurate assessment of the right ventri-
cle and pulmonary artery flow. In current clinical prac-
tice, it is an especially useful tool in patients with a
diagnosis of (or suspected of having) PAH associated
with congenital heart disease. However it also allows
discrimination of other features which might point to an
alternative etiology. It is a flexible research tool which
has opened new avenues for understanding treatment
effects, outcomes and pathogenesis. It appears inevitable
that its place in the management of PH will evolve as
evidence supporting its use accumulates.
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